Alkermes/Reliant merger
Executive Summary
Reliant will become a wholly-owned subsidiary of Alkermes following completion of merger announced March 21. Alkermes already owned 18% of the Liberty Corner, New Jersey-based company; it is acquiring the remaining shares through a stock transaction valued at $934 mil. The company will gain rights to three product families through the acquisition: Lescol, DynaCirc and Axid. Reliant's sales and promotional revenue from the products was $277 mil. in 2001...
You may also be interested in...
Alkermes/Reliant end merger
Alkermes and Reliant are terminating their proposed merger "because of market conditions," CEO Richard Pops tells analysts Aug. 14. The merger, announced March 21, would have given Alkermes the rights to three Reliant products: Lescol, DynaCirc and Axid (1"The Pink Sheet" March 25, In Brief)...
Alkermes/Reliant Merger: Can Lescol Follow Altace Model?
Alkermes hopes Lescol will follow the model of King's Altace as a late bloomer in the cardiovascular market following the proposed acquisition of Reliant Pharmaceuticals
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”